Los Angeles Capital Management
XERS icon

Los Angeles Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Los Angeles Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.59K Sell
791
-17,110
-96% -$113K ﹤0.01% 2151
2025
Q4 		$174K Hold
17,901
– – ﹤0.01% 1281
2025
Q3 		$146K Sell
17,901
-2,481
-12% -$16.5K ﹤0.01% 1305
2025
Q2 		$95.2K Buy
+20,382
New +$93.4K ﹤0.01% 1256

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Los Angeles Capital Management's XERS Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Xeris Biopharma Holdings (XERS) stake by 96% in Q1 2026, selling an estimated $113K and leaving 791 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2151.

Los Angeles Capital Management first reported a position in XERS in Q2 2025 and has held it in 4 quarters since. The position peaked at $174K in Q4 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Los Angeles Capital Management held 791 shares of Xeris Biopharma Holdings worth $4.59K as of Q1 2026.
  • Los Angeles Capital Management sold 17,110 Xeris Biopharma Holdings shares in Q1 2026, an estimated $113K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2151 holding.
  • Los Angeles Capital Management first reported a position in Xeris Biopharma Holdings in Q2 2025 and has held it in 4 quarters since.
  • Los Angeles Capital Management's Xeris Biopharma Holdings position peaked at $174K in Q4 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.